KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Expenses (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Operating Expenses for 16 consecutive years, with $965.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses rose 38.23% year-over-year to $965.3 million, compared with a TTM value of $3.2 billion through Dec 2025, up 32.46%, and an annual FY2025 reading of $3.2 billion, up 32.46% over the prior year.
  • Operating Expenses was $965.3 million for Q4 2025 at Alnylam Pharmaceuticals, up from $881.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $965.3 million in Q4 2025 and bottomed at $360.0 million in Q1 2022.
  • Average Operating Expenses over 5 years is $556.2 million, with a median of $537.2 million recorded in 2023.
  • The sharpest move saw Operating Expenses decreased 1.05% in 2022, then skyrocketed 52.48% in 2025.
  • Year by year, Operating Expenses stood at $453.1 million in 2021, then increased by 15.57% to $523.6 million in 2022, then rose by 6.2% to $556.1 million in 2023, then increased by 25.57% to $698.3 million in 2024, then soared by 38.23% to $965.3 million in 2025.
  • Business Quant data shows Operating Expenses for ALNY at $965.3 million in Q4 2025, $881.0 million in Q3 2025, and $789.9 million in Q2 2025.